{"id":"W4220702214","doi":"10.1136/jitc-2021-003569","title":"Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"Research and Development; National Cancer Institute; Sanofi; Merck","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Aflibercept; Melanoma; Adverse effect; Population; Cancer; Gastroenterology; Bevacizumab; Immunotherapy; Cancer research; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001775101,0.001349917,0.001687734,0.0004115063,0.0004211969,0.0008135313,0.000817743,0.0008732566,0.002353105],"category_scores_gemma":[0.0007174826,0.0005210735,0.0008910138,0.0004684169,0.0007069161,0.0005326792,0.0003089911,0.003361219,0.0008086836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009498784,"about_ca_system_score_gemma":0.001731948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008928758,"about_ca_topic_score_gemma":0.001695542,"domain_scores_codex":[0.9995695,0.0001903509,0.00002797882,0.0000688978,0.00005188289,0.00009142607],"domain_scores_gemma":[0.9992964,0.00008360125,0.0001536909,0.00005180366,0.00004859709,0.0003658656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4591815,0.1258876,0.02671833,0.001300215,0.002416873,0.0007970721,0.0006995603,0.005471841,0.1982332,0.0004861049,0.007813401,0.1709943],"study_design_scores_gemma":[0.4720151,0.4906599,0.02023544,0.00004574634,0.0005428124,0.0008059807,0.00006639944,0.001856188,0.009646444,0.0001704598,0.003932611,0.00002301045],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990392,0.002369368,0.0009419158,0.0005224817,0.00008549973,0.003481011,0.0006421403,0.0000962636,0.001469441],"genre_scores_gemma":[0.9903716,0.001348179,0.002691345,0.0005490074,0.0001252895,0.002286041,0.00166111,0.00002767693,0.0009397126],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002353105,"threshold_uncertainty_score":0.009387732,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01343918754929706,"score_gpt":0.339573802387077,"score_spread":0.3261346148377799,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}